J&J Settles Pfizer's Antitrust Suit Over Remicade Biosimilar

Law360 (July 21, 2021, 8:15 PM EDT) -- Pfizer Inc. has agreed to drop its four-year-old suit alleging Johnson & Johnson violated antitrust laws by coercing health insurers into not covering biosimilar versions of J&J's inflammatory disease biologic Remicade, Pfizer confirmed to Law360 on Wednesday.

The parties filed a brief stipulation of dismissal of the case Tuesday, and Pfizer said in a statement provided to Law360 on Wednesday that the companies had reached a confidential agreement. However, it added that Pfizer will continue to sell its rival biosimilar product Inflectra in the U.S.

"Pfizer has begun to see progress in the overall biosimilars marketplace in the U.S.," the company said....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!